News

Filter

1 to 9 of 536 results

Samsung Bioepis seeks EMA approval of Remicade biosimilar SB2

13-03-2015

South Korea-based Samsung Bioepis, a joint venture between Samsung and US biotech firm Biogen Idec, says…

Anti-Arthritics/RheumaticsBiogen IdecBiosimilarsEuropeGenericsJohnson & JohnsonRegulationRemicadeSamsung BioepisSB2

Highlights of EMA’s PRAC March meetings

13-03-2015

The European Medicines Agency has released highlights of the March 9-12 meeting of its Pharmacovigilance…

Anti-Arthritics/RheumaticscodeineEuropeNeurologicalNovartisPharmaceuticalRegulationzoledronic acid

UK’s NICE recommends Stelara for psoriatic arthritis

UK’s NICE recommends Stelara for psoriatic arthritis

12-03-2015

Medicines cost watchdog for England, the National Institute for Health and Clinical Excellence (NICE),…

Anti-Arthritics/RheumaticsBiotechnologyInflammatory diseasesJanssenJohnson & JohnsonRegulationStelaraUK

AbbVie acquisition of Pharmacyclics will help secure future cash flows as Humira biosimilars loom, says analyst

06-03-2015

US drugmaker AbbVie’s acquisition of Pharmacyclics, valued at $21 billion, will help the company alleviate…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyHematologyHumiraImbruvicaMergers & AcquisitionsOncologyPharmacyclics

US court rules Actavis’ Atelvia patents invalid

US court rules Actavis’ Atelvia patents invalid

05-03-2015

The US District Court for the District of New Jersey has found that Ireland-headquartered Actavis’…

ActavisAnti-Arthritics/RheumaticsAtelviaGenericsLegalPatentsRisedronate SodiumTeva Pharmaceutcal IndustriesUSAWomen's Health

ABPI Rheumatology Initiative report says the UK does not prioritize rheumatoid arthritis enough

ABPI Rheumatology Initiative report says the UK does not prioritize rheumatoid arthritis enough

04-03-2015

Rheumatoid arthritis is not given a high enough priority in the UK, according to a new report from the…

Anti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalResearchSocial IssuesUK

Mundipharma launches monoclonal antibody Remsima in six European markets

26-02-2015

Privately-held UK-based drugmaker Mundipharma International is launching Remsima (infliximab) this month…

Anti-Arthritics/RheumaticsEuropeMarkets & MarketingMundipharmaPharmaceuticalRemsima

Sanofi collaborates with Lead Pharma for autoimmune disease development

Sanofi collaborates with Lead Pharma for autoimmune disease development

18-02-2015

French pharma major Sanofi has entered into a research collaboration and license agreement with privately-held…

Anti-Arthritics/RheumaticsLead PharmaLicensingPharmaceuticalResearchSanofi

1 to 9 of 536 results

Back to top